» Articles » PMID: 37279475

Cationic Proteins from Eosinophils Bind Bone Morphogenetic Protein Receptors Promoting Vascular Calcification and Atherogenesis

Abstract

Aims: Blood eosinophil count and eosinophil cationic protein (ECP) concentration are risk factors of cardiovascular diseases. This study tested whether and how eosinophils and ECP contribute to vascular calcification and atherogenesis.

Methods And Results: Immunostaining revealed eosinophil accumulation in human and mouse atherosclerotic lesions. Eosinophil deficiency in ΔdblGATA mice slowed atherogenesis with increased lesion smooth muscle cell (SMC) content and reduced calcification. This protection in ΔdblGATA mice was muted when mice received donor eosinophils from wild-type (WT), Il4-/-, and Il13-/- mice or mouse eosinophil-associated-ribonuclease-1 (mEar1), a murine homologue of ECP. Eosinophils or mEar1 but not interleukin (IL) 4 or IL13 increased the calcification of SMC from WT mice but not those from Runt-related transcription factor-2 (Runx2) knockout mice. Immunoblot analyses showed that eosinophils and mEar1 activated Smad-1/5/8 but did not affect Smad-2/3 activation or expression of bone morphogenetic protein receptors (BMPR-1A/1B/2) or transforming growth factor (TGF)-β receptors (TGFBR1/2) in SMC from WT and Runx2 knockout mice. Immunoprecipitation showed that mEar1 formed immune complexes with BMPR-1A/1B but not TGFBR1/2. Immunofluorescence double-staining, ligand binding, and Scatchard plot analysis demonstrated that mEar1 bound to BMPR-1A and BMPR-1B with similar affinity. Likewise, human ECP and eosinophil-derived neurotoxin (EDN) also bound to BMPR-1A/1B on human vascular SMC and promoted SMC osteogenic differentiation. In a cohort of 5864 men from the Danish Cardiovascular Screening trial and its subpopulation of 394 participants, blood eosinophil counts and ECP levels correlated with the calcification scores of different arterial segments from coronary arteries to iliac arteries.

Conclusion: Eosinophils release cationic proteins that can promote SMC calcification and atherogenesis using the BMPR-1A/1B-Smad-1/5/8-Runx2 signalling pathway.

Citing Articles

Thrombotic prosthetic valve dysfunction requiring valve re-replacement after mitral valve replacement for caseous calcification with hypereosinophilic syndrome: a case report.

Miyazawa K, Imai E, Kodaira A, Ota T, Yokozuka M Eur Heart J Case Rep. 2025; 9(2):ytaf024.

PMID: 39917781 PMC: 11799941. DOI: 10.1093/ehjcr/ytaf024.


Exploratory review on the effect of on signaling pathways.

Xu Lou I, Yu X, Chen Q Front Pharmacol. 2024; 15:1510307.

PMID: 39726784 PMC: 11670317. DOI: 10.3389/fphar.2024.1510307.


Differential roles of eosinophils in cardiovascular disease.

Xu J, Guo J, Liu T, Yang C, Meng Z, Libby P Nat Rev Cardiol. 2024; 22(3):165-182.

PMID: 39285242 DOI: 10.1038/s41569-024-01071-5.


Association between asthma and cardiovascular diseases: A longitudinal follow-up study using a national health screening cohort.

Choi H, Kwon M, Kim J, Kim S, Kim J, Park J World Allergy Organ J. 2024; 17(6):100907.

PMID: 38873616 PMC: 11170141. DOI: 10.1016/j.waojou.2024.100907.


PBX/Knotted 1 homeobox-2 (PKNOX2) is a novel regulator of myocardial fibrosis.

Chen L, Li H, Liu X, Zhang N, Wang K, Shi A Signal Transduct Target Ther. 2024; 9(1):94.

PMID: 38644381 PMC: 11033280. DOI: 10.1038/s41392-024-01804-5.


References
1.
Hinck A . Structural studies of the TGF-βs and their receptors - insights into evolution of the TGF-β superfamily. FEBS Lett. 2012; 586(14):1860-70. DOI: 10.1016/j.febslet.2012.05.028. View

2.
Yang C, Li J, Deng Z, Luo S, Liu J, Fang W . Eosinophils protect pressure overload- and β-adrenoreceptor agonist-induced cardiac hypertrophy. Cardiovasc Res. 2022; 119(1):195-212. PMC: 10022866. DOI: 10.1093/cvr/cvac060. View

3.
Leopold J . Cellular mechanisms of aortic valve calcification. Circ Cardiovasc Interv. 2012; 5(4):605-14. PMC: 3427002. DOI: 10.1161/CIRCINTERVENTIONS.112.971028. View

4.
Kranzhofer R, Schmidt J, Pfeiffer C, Hagl S, Libby P, Kubler W . Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999; 19(7):1623-9. DOI: 10.1161/01.atv.19.7.1623. View

5.
Diederichsen A, Rasmussen L, Sogaard R, Lambrechtsen J, Steffensen F, Frost L . The Danish Cardiovascular Screening Trial (DANCAVAS): study protocol for a randomized controlled trial. Trials. 2015; 16:554. PMC: 4670524. DOI: 10.1186/s13063-015-1082-6. View